Business context and reporting period
This summary covers Apollo Medical Holdings, Inc.’s Form 10-K for the fiscal year ended January 31, 2012, compared with the year ended January 31, 2011. The filing is for Apollo Medical Holdings—not a registrant named Astrana Health, Inc.; verify the company and filing identity.
Apollo managed affiliated physician practices providing hospitalist and hospital-based services in California, serving 23 hospitals as of January 31, 2012. Its growth strategy combined new contracts and acquisitions. During the year, it acquired Aligned Healthcare Group (AHI) and Pulmonary Critical Care Management (PCCM), with PCCM’s consolidation bringing the Los Angeles Lung Center into the consolidated financial statements.
Financial performance and liquidity
| Metric | FY ended Jan. 31, 2012 | FY ended Jan. 31, 2011 |
|---|---|---|
| Revenue | $5.111 million | $3.897 million |
| Gross profit | $978,407; 19.1% margin | $581,862; 14.9% margin |
| Operating income (loss) | $(413,335); (8.1%) margin | $4,015 |
| Net income (loss) | $(720,346); $(0.02) per share | $(156,331); $(0.01) per share |
| Cash from (used in) operating activities | $(385,455) | $(245,031) |
| Cash and cash equivalents at year-end | $164,361 | $397,101 |
Revenue increased 31.2%, attributed to new contracts and the PCCM acquisition. Cost of services was $4.132 million, or 80.9% of revenue, compared with 85.1% a year earlier. General and administrative expense rose 143.4% to $1.379 million, or 27.0% of revenue, from $566,649, or 15.0%.
Year-end current assets were $1.249 million and current liabilities were $1.515 million, implying negative working capital of approximately $266,000. The balance sheet reported total liabilities of $1.785 million and a stockholders’ deficit of $421,220. Debt presentation requires care: the balance sheet reports convertible notes net of discount of $746,366 ($596,366 current and $150,000 noncurrent), while management describes total borrowings of $1.399 million; the notes disclose $1.25 million principal on the 10% notes plus $150,000 of 8% notes. The 10% notes were due January 31, 2013.
Investing activities provided $157,005, primarily from $164,210 cash received upon consolidation of a variable interest entity. Financing activities used $4,290, including $154,290 in distributions to a non-controlling interest, partly offset by $150,000 in note proceeds. The company reported an accumulated deficit of $2.118 million.
Material changes, outlook, and risks
- Net loss widened to $720,346 from $156,331. The company cited higher G&A, bad-debt expense, acquisition and legal costs, and financing costs. FY2012 included a $210,000 goodwill impairment related to AHI and a $120,000 warrant-liability charge.
- AHI’s anticipated contracts did not materialize as expected; the company impaired the full $210,000 goodwill recorded for that acquisition. PCCM’s acquisition brought $164,210 of cash into consolidation and resulted in $164,276 of non-controlling interest.
- The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, negative working capital, operating cash outflow, and deficit equity. Management planned to seek additional capital but gave no assurance it would succeed; it warned that failure to raise substantial capital timely could force cessation of operations.
- No quantified financial guidance was provided. Management described plans for organic growth, physician recruitment, new contracts, and acquisitions, subject to available capital and successful execution.
- Key exposures include Medicare and other payer reimbursement changes, delayed or uncollectible receivables, customer concentration, healthcare regulatory and compliance risks, malpractice claims, acquisition execution, and ability to raise capital. Three customers represented 34%, 17%, and 7.6% of FY2012 revenue.
- Disclosure controls and internal control over financial reporting were deemed ineffective, with three material weaknesses: lack of written control documentation, insufficient segregation of duties, and inadequate review and supervision. The company said it was taking remediation steps; the auditor did not attest to internal controls.
- Subsequent to year-end, an entity affiliated with director Gary Augusta provided a $270,000 seven-month loan; the company prepaid $15,000 interest and paid $5,000 closing costs. The filing also disclosed an absence of a formal ethics and compliance program.
Important facts for investors to verify
- Confirm the registrant and reporting period: the supplied filing identifies Apollo Medical Holdings, Inc. and fiscal year ended January 31, 2012, notwithstanding the request metadata naming Astrana Health and “2011 Q4.”
- Reconcile the debt figures, including principal, discounts, derivative and warrant liabilities, maturity dates, and the apparent difference between reported borrowings and balance-sheet carrying values.
- Review the going-concern disclosures, available financing, subsequent $270,000 related-party loan terms, and the company’s ability to fund operations and meet near-term obligations.
- Assess the AHI impairment and acquisition outcomes, PCCM/LALC consolidation, and whether new contracts and growth plans produced the expected revenue and cash generation.
- Examine receivable collectability, customer concentration, the increase in bad-debt expense, and the effectiveness of remediation for the reported material weaknesses.